InsiderClue
Stocks · Health care · Surgical & Medical Instruments & Apparatus

KESTRA MEDICAL TECHNOLOGIES, LTD.

KMTS Clue Score63
United States Fiscal year ends April CIK 0001877184
$26.91 -0.26% Close, 12 Oct 2026
Alert on the numbers Alert on insider trades
Price $26.91 +19.18% Close, 12 Oct 2026

Closing prices at the end of each trading day, from 6 Mar 2025. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2024Revenue27.8Operating income−85.1Net income−94.1EPS, diluted−5.07Fiscal year 2025Revenue59.8 +115.1%Operating income−106.4Net income−113.8EPS, diluted−5.13Fiscal year 2026Revenue95.1 +59.0%Operating income−134.7Net income−131.6EPS, diluted−2.43
FY2024FY2025FY2026
Revenue 27.8 59.8 95.1
Growth +115.1% +59.0%
Operating income −85.1 −106.4 −134.7
Net income −94.1 −113.8 −131.6
Growth
EPS, diluted −5.07 −5.13 −2.43

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Gross marginOperating marginNet margin
Fiscal year 2024Gross margin1.3%Operating margin−305.8%Net margin−338.4%Free cash flow margin−303.7%Fiscal year 2025Gross margin40.5%Operating margin−177.8%Net margin−190.3%Free cash flow margin−168.1%Fiscal year 2026Gross margin51.4%Operating margin−141.6%Net margin−138.4%Free cash flow margin−122.6%
FY2024FY2025FY2026
Gross margin 1.3% 40.5% 51.4%
Operating margin −305.8% −177.8% −141.6%
Net margin −338.4% −190.3% −138.4%
Free cash flow margin −303.7% −168.1% −122.6%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2024Operating cash flow−72.2Capital expenditure−12.2Free cash flow−84.5Fiscal year 2025Operating cash flow−77.6Capital expenditure−22.9Free cash flow−100.5Fiscal year 2026Operating cash flow−81.7Capital expenditure−34.9Free cash flow−116.6
FY2024FY2025FY2026
Operating cash flow −72.2 −77.6 −81.7
Capital expenditure −12.2 −22.9 −34.9
Free cash flow −84.5 −100.5 −116.6
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2024Cash8.2Total debt42.5Net cash (debt)−34.3Shareholders’ equity−209.4Fiscal year 2025Cash237.6Total debt41.1Net cash (debt)196.5Shareholders’ equity205.4Debt to equity0.20Fiscal year 2026Cash99.7Total debt42.6Net cash (debt)57.1Shareholders’ equity259.7Debt to equity0.16
FY2024FY2025FY2026
Cash 8.2 237.6 99.7
Total debt 42.5 41.1 42.6
Net cash (debt) −34.3 196.5 57.1
Shareholders’ equity −209.4 205.4 259.7
Debt to equity n/a 0.20 0.16

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2026 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending April, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2024 30 Apr 2024 FY2025 30 Apr 2025 FY2026 30 Apr 2026
Margins
1.3% 40.5% 51.4%
−305.8% −177.8% −141.6%
−338.3% −190.1% −138.0%
−338.4% −190.3% −138.4%
−303.7% −168.1% −122.6%
Spending
55.7% 26.2% 20.5%
251.4% 192.2% 172.5%
44.0% 38.3% 36.7%
Returns
n/a −55.4% −50.7%
−204.8% −38.5% −36.7%
Balance and payout
n/a 0.20 0.16
170.2% 30.5% 27.6%